CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

June 24, 2019 · Phase 2 readout

ABBV Phase 2 readout: a completed outcome, -16.3%

On June 24, 2019, Depatuxizumab mafodotin — AbbVie Inc. (Glioblastoma) reached its Phase 2 readout. The result was a completed outcome, and the stock moved -16.3% in the window around the event.

The move

$78.45
1d before
$78.45
Event day
$65.70
1d after
$72.72
5d after

Pre-catalyst setup

1235%
30-day volatility
2.1×
volume spike